Agios is passionately committed to applying our leadership in the field of cellular metabolism to create life-changing therapies for people living with genetically defined diseases. The bonds we build with patient communities, healthcare professionals, partners and colleagues help elevate our thinking and propel our science to new heights. These connections, combined with our cellular metabolism expertise, have fueled the development of our first-in-class pyruvate kinase (PK) activator, mitapivat, as well as other investigational therapies.